Low dose ATG-Fresenius for GVHD prophylaxis: a comparative study with ATG-Thymoglobulin

Keyphrases

• Graft-versus-host Disease Prophylaxis 100%
• Antithymocyte Globulin 100%
• Fresenius 100%
• Thymoglobulin 100%
• T-group 33%
• Graft-versus-host Disease (GvHD) 22%
• Chronic Graft-versus-host Disease (cGVHD) 22%
• F-group 16%
• Disease Prevention 11%
• Cumulative Incidence 11%
• HLA Matching 11%
• No Significant Difference 5%
• Relapse-free Survival 5%
• Overall Survival 5%
• Lymphoma Patients 5%
• Cyclosporine 5%
• Multivariate Analysis 5%
• High Dose 5%
• Optimal Dose 5%
• Disease-free 5%
• Viremia 5%
• Myelodysplastic Syndrome 5%
• Bacteremia 5%
• Baseline Characteristics 5%
• Safety Outcomes 5%
• Allogeneic Transplantation 5%
• Myeloid Leukemia 5%
• EBV DNA 5%
• Myeloablative Conditioning 5%
• Post-transplant Lymphoproliferative Disorder 5%
• Non-relapse Mortality 5%
• Relapse Incidence 5%
• Mismatched Related Donor 5%
• CMV Reactivation 5%
• Efficacy Outcomes 5%

Medicine and Dentistry

• Low Drug Dose 100%
• Graft Versus Host Reaction 100%
• Thymocyte Antibody 100%
• Cumulative Incidence 10%
• Prophylaxis 10%
• Recurrence Free Survival 5%
• Overall Survival 5%
• Prospective Study 5%
• Cyclosporine 5%
• Bloodstream Infection 5%
• Allograft 5%
• Chronic Graft Versus Host Disease 5%
• Myeloid Leukemia 5%
• Myelodysplastic Syndrome 5%
• Drug Megadose 5%
• Epstein Barr Virus 5%
• Viremia 5%
• Acute Graft Versus Host Disease 5%
• Optimal Drug Dose 5%
• Posttransplant Lymphoproliferative Disease 5%
• Non-Relapse Mortality 5%
• Myeloablative Conditioning 5%
• Multivariate Analysis 5%

Immunology and Microbiology

• Low Drug Dose 100%
• Graft-Versus-Host Disease 100%
• Anti-Thymocyte Globulin 100%
• Recurrence Free Survival 5%
• Overall Survival 5%
• Myeloid 5%
• Ciclosporin 5%
• Drug Megadose 5%
• Chronic Graft Versus Host Disease 5%
• Lymphoproliferative Disorders 5%
• Viremia 5%
• Acute Graft Versus Host Disease 5%
• Epstein Barr Virus 5%
• Allograft 5%
• Optimal Drug Dose 5%